The pharmacology of reversible monoamine oxidase inhibitors.
The older monoamine oxidase inhibitors (MAOIs) are mechanism-based, irreversible inhibitors of MAO; most inhibit both the A and B forms of MAO. Several of the drugs are hydrazine derivatives which have non-specific effects other than MAO inhibition. These properties convey disadvantages, which may be seen as serious, though infrequent, adverse events--the 'cheese effect', hepatotoxicity, amphetamine-like activity, orthostatic hypotension and anticholinergic effects. New, reversible MAOIs stem from a variety of chemical classes and are more specific in their effects, with relatively rapid onset of action, direct relationship between plasma concentration and pharmacological effect, and no prolonged carry-over phenomena.
Amrein
R
R
F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Allen
S R
SR
Guentert
T W
TW
Hartmann
D
D
Lorscheid
T
T
Schoerlin
M P
MP
Vranesic
D
D
D000284:Administration, Oral; D000928:Antidepressive Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D003866:Depressive Disorder / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000493:pharmacokinetics* / Q000627:therapeutic use
D000928:Antidepressive Agents; D008996:Monoamine Oxidase Inhibitors